Acadia Pharmaceutical logo vector
Acadia's lead product, Nuplazid (pimavanserin), is an FDA-approved treatment for PDP. The company is also developing other promising therapies for CNS disorders, including tozadenant for treatment of levodopa-induced dyskinesia in Parkinson's disease, and ACP-5216 for treatment of Rett syndrome.
